What Plectonic Biotech does

Plectonic Biotech GmbH is a German preclinical-stage biotechnology company headquartered in Hallbergmoos near Munich, founded in 2022–2023 as a spin-off from the Technical University of Munich. The company develops LOGIBODY (LOGIc-gated antiBODies), a DNA nanotechnology-based immunotherapy platform that uses DNA-origami scaffolds as molecular logic gates to activate immune responses only when a specific tumor antigen pattern is detected. LOGIBODYs combine antibody-based targeting with DNA nanostructure stability and modularity, enabling if-then conditional T cell engagement intended to reduce on-target/off-tumor toxicity and uncontrolled cytokine release relative to conventional bispecific antibodies.

The company's product strategy is a preclinical pipeline across two undisclosed oncology indications, with stated optionality to extend LOGIBODY's logic-gated mechanism into autoimmune diseases. Co-founders Dr. Klaus Wagenbauer (CEO), Dr. Jonas Funke (CTO), Dr. Benjamin Kick (COO), and co-founder Prof. Hendrik Dietz bring more than 13 years of DNA nanotechnology expertise from TUM; co-inventor Benjamin Kick has also developed scalable, cost-efficient DNA nanostructure manufacturing methods relevant to industrial supply. The company's intellectual property position includes co-invented LOGIBODY and Ultra-Beacon technologies and multiple granted patents covering therapeutic and diagnostic applications of DNA nanotechnology, with foundational research published in Nature Nanotechnology in 2023.

Plectonic is pre-commercial with no product revenue; non-dilutive grant funding includes the €2.5M m4 Award (BioM, 2019), GO-Bio (BMBF) support, and a multi-year SPRIND commitment announced in 2023. The go-to-market posture is partnership-driven: the company explicitly seeks pharmaceutical and biotech partners for clinical development, manufacturing, and eventual commercialization, while building internal CMC and preclinical capabilities and a 2025 collaboration with Sonrai Analytics for AI-powered antigen discovery. Customers are therefore future enterprise pharma/biotech licensing partners rather than end-patient or provider buyers at this stage.

Name

Plectonic Biotech

Legal name

Plectonic Biotech GmbH

Website

https://plectonic.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Plectonic Biotech GmbH is a German preclinical-stage biotech, spun out of the Technical University of Munich, developing LOGIBODY — a DNA-nanotechnology immunotherapy platform using logic-gated antibodies to enable precise, conditional tumor targeting in oncology and autoimmune disease, and seeking pharma partners for clinical development.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• DNA nanotechnology therapeutics
• Cancer immunotherapy platform
• Logic-gated antibodies
• Bispecific T cell engagers
• Preclinical oncology biotech

Headquarters

HQ city

Garching Bei München

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Distribution channels1 record

Marketing channels3 records

Core offering

Plectonic Biotech develops the LOGIBODY Technology Platform, a DNA nanotechnology-based immunotherapy platform for targeted cancer therapy. LOGIBODYs are logic-gated antibodies built on DNA nanostructure scaffolds that selectively activate immune cells only when a specific tumor antigen pattern is detected, combining antibody specificity with DNA-based structural stability and modularity. The platform is being advanced through preclinical development for two undisclosed oncology indications with potential expansion into autoimmune disease applications.

Product overview

Plectonic Biotech offers the LOGIBODY Technology Platform as its core product—a DNA-based immunotherapy platform designed for targeted cancer therapy. The platform combines the specificity of antibody-based targeting with the enhanced stability and modularity of DNA nanostructures, implementing a novel logic-gated mechanism that enables precise tumor targeting while reducing off-target effects. LOGIBODYs function as intelligent antibodies that activate selectively at the tumor site, recognizing tumors by their unique antigen patterns rather than single target molecules, and can be flexibly customized to target different cancer types by swapping antibody modules.

Differentiator

Problem solved

Functional benefit

Products and services

• LOGIBODY Technology Platform DNA-based immunotherapy platform combining antibody specificity with DNA nanostructure stability and modularity. LOGIBODYs (LOGIc-gated antiBODies) are intelligent antibodies built on a DNA scaffold acting as a molecular switch; they recognize tumors by their unique multi-antigen pattern rather than single targets and only activate immune cells when that pattern is detected, enabling selective, reversible, site-specific T cell engagement. The platform is designed for pharmaceutical and biotech partners for preclinical and clinical development in oncology and autoimmune indications.

Quantifiable outcome

• Precise immune activation with reduced side effects demonstrated in Nature Nanotechnology publication (2023)

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Sonrai AnalyticscoreTechnology or Integration · 1 January 2025Strategic collaboration to integrate high-resolution, AI-powered antigen discovery into LOGIBODY technology development. Aims to drive safer, more targeted cancer immunotherapies through enhanced antigen identification capabilities.
• TUM (Technical University of Munich)coreStrategic or Co-development PartnerAcademic institution from which Plectonic Biotech spun off. Founding research on LOGIBODY technology originated from TUM laboratories. Company maintains close ties with TUM researchers and facilities.
• BioMminorStrategic or Co-development PartnerBavarian Biotech Cluster organization supporting biotech innovation. Provided m4 Award funding in 2019 for early research.
• EIT Health EUminorStrategic or Co-development PartnerEuropean health innovation community providing support and resources for healthcare innovation across Europe.
• Plectonic Logibody GmbHcoreStrategic or Co-development PartnerAffiliated entity executing research on LOGIBODY technology. Company founded as spin-off with research executed through this partner organization.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Adagene: Adagene uses AI-driven antibody discovery and engineering to develop precision antibodies including conditionally activated formats. The company represents a peer in next-generation antibody engineering combining computational approaches with novel antibody architectures, paralleling Plectonic's LOGIBODY + Sonrai AI strategy.
• Numab Therapeutics: Numab develops multispecific antibodies using its proprietary lambda-cap and Fv-Ig formats that combine multiple binding specificities in single molecules. Both companies engineer multi-specificity antibody constructs designed to achieve selective biological function through combinatorial antigen recognition.
• BioAtla: BioAtla develops Conditionally Active Biologics (CABs), which are antibodies and other proteins engineered to activate selectively in the tumor microenvironment using a similar logic-gated mechanism to LOGIBODY. Both companies are pursuing the same strategic thesis: that conditional, tumor-restricted activation can overcome the safety ceiling of conventional antibody therapies.
• Molecular Partners: Molecular Partners develops DARPins (Designed Ankyrin Repeat Proteins), a non-antibody scaffold alternative to traditional monoclonal antibodies for therapeutic applications. Both companies engineer novel protein scaffolds as alternatives to conventional antibodies, pursuing similar therapeutic goals through different structural approaches.
• Maverick Therapeutics (Takeda): Maverick developed logic-gated T-cell engagers designed to activate only when both a tumor antigen and a second contextual marker are detected — directly analogous to Plectonic's LOGIBODY mechanism. Acquired by Takeda in 2021, Maverick represents the most direct mechanistic parallel in oncology immunotherapy.
• CytomX Therapeutics: CytomX's Probody platform uses conditionally activated antibodies that are masked until activated by tumor-associated proteases — conceptually the closest commercial-stage analogue to Plectonic's logic-gated LOGIBODY approach. Both companies target the same unmet need of reducing on-target/off-tumor toxicity in antibody therapeutics.
• Crescendo Biologics: Crescendo Biologics develops T-cell engagers based on a proprietary Humabody VH domain platform — a non-standard antibody scaffold for engaging immune cells against tumors. Both companies pursue T-cell-engaging therapeutics using novel protein scaffolds as alternatives to conventional bispecific antibodies.

Broad incumbents

• Philogen: Philogen develops antibody-based therapeutics for oncology and inflammatory diseases, including antibody-cytokine fusion proteins and targeted immunocytokines. As a European clinical-stage antibody therapeutics company, Philogen represents both a comparable regional player and a potential strategic partner for Plectonic's T-cell engaging platform.
• Genmab: Genmab is the leading independent bispecific antibody company with its Duobody platform, generating products like epcoritamab. As the established leader in bispecific antibody engineering for oncology, Genmab represents both a potential partner and the competitive benchmark that any next-generation bispecific or logic-gated platform must outperform.

Emerging players

• Cullinan Oncology: Cullinan Oncology is a clinical-stage biopharmaceutical company developing a diversified pipeline of oncology therapeutics including T-cell engagers and bispecific antibodies. Both companies pursue multi-program oncology strategies targeting immune engagement with novel modalities, though Cullinan is several years ahead clinically.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/plectonic-biotech

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Plectonic Biotech